ArticleJournal of veterinary internal medicine2026
The effect of a single dose of flunixin meglumine on shedding of inoculated bovine herpesvirus-1 in weaned calves.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe effects of a Food and Drug Administration approved non-steroidal anti-inflammatory drug (NSAID) on bovine herpesvirus-1 (BHV-1) shedding in cattle has not been investigated. HYPOTHESIS/
objectivesThe hypothesis of this study was that a single dose of flunixin meglumine would increase the magnitude and duration of viral shedding in calves inoculated with BHV-1. ANIMALS: Twelve, 6- to 8-week-old, commercial Holstein cross-bred steer calves purchased for research, and BHV-1 polymerase chain reaction (PCR) negative on intake (day-4).
methodsIn this randomized-control study, calves were equally divided into treatment (FM) and control (CON) groups. All calves were inoculated intranasally with approximately 4 mL of 1 × 105 TCID50 of BHV-1. Nasal swabs for BHV-1 PCR testing were collected every 24 h after inoculation. Calves in the FM group were treated with 2.2 mg/kg of flunixin meglumine intravenously once after the first BHV-1 PCR positive sample. Magnitude and duration of viral shedding between groups was compared, and a P-value of <.05 was considered significant.
resultsLeast square mean of the total Log10 AUC of the FM group was 6.11 (95% CI: 4.62-7.60) and CON group was 7.49 (95% CI: 6.00-8.98). The FM group's mean duration from initial to last positive PCR was 7.33 days ± SD: 4.41 and the CON group's mean was 9.5 days ± SD: 5.80. CONCLUSIONS AND CLINICAL IMPORTANCE: Intranasal inoculation with BHV-1 resulted in a wide range of shedding magnitude and duration. Flunixin meglumine administration in BHV-1 challenged calves did not result in an increase in magnitude or duration of viral shedding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.